• Heather Green and Andrew M Jones.
• Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester NHS Trust, Manchester, United Kingdom.
• Semin Respir Crit Care Med. 2015 Apr 1;36(2):225-35.

AbstractChronic pulmonary sepsis is the predominant cause of morbidity for patients with cystic fibrosis (CF) and non-CF bronchiectasis. Previously it was thought that respiratory infection in these patients was mostly limited to a very small number of typical pathogens; however, in recent years there have been increasing reports of infection with other emerging potential pathogens including Burkholderia, Stenotrophomonas, Achromobacter, Ralstonia, Pandoraea, nontuberculous mycobacteria, and fungal species. Furthermore, culture-independent methodologies have established that the lungs of patients with CF and non-CF bronchiectasis comprise mixed microbiological communities of aerobic and anaerobic bacteria, fungal and viral species, collectively referred to as the lung microbiome. This article addresses the clinical relevance of emerging pathogens and the lung microbiome in CF and non-CF bronchiectasis.Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

26 keywords...

hide…